SLSC can support you with developing new indications as part of life cycle management activities, as well as with pharmacovigilance services by writing:
- Target Product Profiles (TPP) for parallel indications
- Clinical Development Plans (CDP) for parallel indications
- Medical Safety Assessments of new safety topics
- Postmarketing dysproportionality analyses
- Periodic benefit-risk evaluation reports (PBRER)
- Answers to HA questions